Michael A Tainsky
Overview
Explore the profile of Michael A Tainsky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
79
Citations
1667
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McCarthy-Leo C, Baughan S, Dlugas H, Abraham P, Gibbons J, Baldwin C, et al.
Cancer Genet
. 2024 Aug;
288-289:10-19.
PMID: 39208550
The cell cycle checkpoint kinase 2 (CHEK2) is a tumor suppressor gene coding for a protein kinase with a role in the cell cycle and DNA repair pathways. Variants within...
2.
McCarthy-Leo C, Brush G, Pique-Regi R, Luca F, Tainsky M, Finley Jr R
PLoS Genet
. 2024 Aug;
20(8):e1011375.
PMID: 39146382
Loss of function mutations in the checkpoint kinase gene CHEK2 are associated with increased risk of breast and other cancers. Most of the 3,188 unique amino acid changes that can...
3.
McCarthy-Leo C, Darwiche F, Tainsky M
Cancers (Basel)
. 2022 Nov;
14(21).
PMID: 36358700
Repair of a DNA double-strand break relies upon a pathway of proteins to identify damage, regulate cell cycle checkpoints, and repair the damage. This process is initiated by a sensor...
4.
Functional analysis of ATM variants in a high risk cohort provides insight into missing heritability
Baughan S, Darwiche F, Tainsky M
Cancer Genet
. 2022 Mar;
264-265:40-49.
PMID: 35354106
Variants of unknown significance (VUS) remain a constant challenge in the diagnosis of hereditary cancer and the counseling of patients with pedigrees suggestive of such a syndrome. In order to...
5.
Chaudhry S, Lopes J, Levin N, Kalpage H, Tainsky M
Cell Death Discov
. 2021 Mar;
7(1):62.
PMID: 33782397
Approximately 25% of all cases of ovarian cancer (OVCA) cases are associated with inherited risk. However, accurate risk assessment is limited by the presence of variants of unknown significance (VUS)....
6.
Baughan S, Tainsky M
Cancers (Basel)
. 2021 Jan;
13(3).
PMID: 33503928
Whole genome analysis and the search for mutations in germline and tumor DNAs is becoming a major tool in the evaluation of risk as well as the management of hereditary...
7.
Hurley L, Levin N, Chatterjee M, Coles J, Muszkat S, Howarth Z, et al.
Cancer Biomark
. 2020 Feb;
27(3):407-421.
PMID: 32083570
Background: The majority of ovarian cancer cases are diagnosed at an advanced stage with poor prognosis. This study evaluates autoantibodies against tumor antigens to identify candidate biomarkers for early detection...
8.
Lopes J, Chaudhry S, Lopes G, Levin N, Tainsky M
Cancer Genet
. 2019 May;
235-236:57-64.
PMID: 31078449
Although 25% of ovarian cancer cases are due to inherited factors, most of the genetic risk remains unexplained. We previously identified candidate genes through germline whole exome sequencing of BRCA1/BRCA2...
9.
Farran B, Albayrak S, Abrams J, Tainsky M, Levin N, Morris R, et al.
Cancer Med
. 2019 Feb;
8(3):920-927.
PMID: 30761774
Novelty and Impact Statement: Our findings suggest that soluble folate receptor (sFR) could be used in both the initial diagnosis and surveillance of patients with ovarian cancer. Our cohort constitutes...
10.
Chaudhry S, Tainsky M
Curr Protoc Bioinformatics
. 2019 Feb;
65(1):e73.
PMID: 30747482
Molecular genetic testing provides the capability for personalized prediction, diagnosis, and pharmacological treatments of disease and disorders. Variant assessment of next-generation sequencing (NGS) is a crucial component of genetic testing...